Colorectal Liver Metastases Clinical Trial
Official title:
Impact of Pre-operative Bevacizumab on Complications After Resection of Colorectal Liver Metastases A Case Matched Control Study
Hypothesis of the study: Neoadjuvant chemotherapy with Bevacizumab impairs postoperative outcome after resection of colorectal liver metastases.
Bevacizumab is a humanized monoclonal antibody against vascular endothelial growth factor
(VEGF) increasingly added to other drugs in the treatment of colorectal cancer. Bev is
typically used in combination with other chemotherapeutic agents such as oxaliplatin,
irinotecan, leucovorin and 5-fluorouracil (5-FU) for treatment of patients with CRLM. The
objective of this study was to assess the impact of neoadjuvant bevacizumab on clinical
outcome after hepatectomy of colorectal liver metastases (CRLM).
Patients, who underwent liver resection due to colorectal liver metastases after neoadjuvant
chemotherapy, operated between 2005 and 2007 will be evaluated retrospectively. The patients
will be distributed in two groups, either with or without bevacicumab. Outcome parameters
are mortality, complications, hospital stay and ICU stay. To increase the power of the study
the total number of patients will be increased by adding patients from other centers.
Results will be adjusted for the propensity of developing complications.
;
Observational Model: Cohort, Time Perspective: Retrospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01255007 -
Comparison of Primovist-enhanced MRI, Diffusion Weighted MRI and Multidetector CT of Colorectal Liver Metastases
|
N/A | |
| Completed |
NCT00779272 -
Impact of Preoperative Chemotherapy on Complications and Regeneration After Resection of Colorectal Liver Metastases
|
N/A | |
| Active, not recruiting |
NCT00797251 -
Anatomical Right Posterior Sectionectomy of the Liver by IOUS-Guided Finger Compression
|
N/A | |
| Recruiting |
NCT06045286 -
High- and Low-dose Radiotherapy Combined With PD-1 Inhibitors for MSS CRLM
|
Phase 1 | |
| Recruiting |
NCT04870879 -
Colorectal Metastasis and Liver Transplantation With Organs From Deceased Donors
|
N/A | |
| Completed |
NCT01799044 -
Pilot-study: Non-thermal Ablation Using Irreversible Electroporation to Treat Colorectal Liver Metastases
|
Phase 1 | |
| Terminated |
NCT00508872 -
Folfox-B Study for Patients With Colorectal Liver Metastases
|
Phase 2 | |
| Recruiting |
NCT05877001 -
The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases
|
Phase 2 | |
| Completed |
NCT02082782 -
Efficacy of Irreversible Electroporation (IRE) for Central Colorectal Liver Metastases
|
Phase 2 | |
| Completed |
NCT00942292 -
The Effect of Fish Oils on Human Hepatic Colorectal Metastases
|
Phase 2 | |
| Recruiting |
NCT01191632 -
Effect of Neoadjuvant Radiation on Tumor Infiltrating T-cells by Low Dose Radiation in Colorectal Liver Metastases
|
Phase 1/Phase 2 | |
| Completed |
NCT00119899 -
Utility of FDG-PET Scan on the Selection of Patients for Resection of Hepatic Colorectal Metastases
|
Phase 3 | |
| Completed |
NCT00184834 -
Quality of Life and Liver Metastases
|
N/A | |
| Completed |
NCT00557557 -
Safety Study of Oxaliplatin and 5-fluorouracil Followed by FUDR for Unresectable Colorectal Liver Metastases
|
Phase 1 | |
| Recruiting |
NCT05468593 -
Patient Outcomes After Hepatic Artery Infusion Pump Placement
|
||
| Completed |
NCT02615665 -
Intratumoral CD3+ and NKp46+ Cells in Colorectal Liver Metastases
|
N/A | |
| Terminated |
NCT01318447 -
CyberKnife® for Hepatic Metastases From Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT00885950 -
Prevention of the Hepatic Sinusoidal Obstruction Syndrome by Means of Anticoagulants
|
N/A | |
| Completed |
NCT02331641 -
Multiple Minor Hepatectomies Versus Major or Extended Hepatectomies for Colorectal Liver Metastases.
|
N/A | |
| Completed |
NCT00600522 -
Alternative Surgical Policy for Central Liver Tumors
|
N/A |